BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
ERBB2
,
calcium channel activity
,
Breast Cancer
,
Embryo
,
Neocentromeres
,
Fluoxetine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
c ets- 2
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
USP39-Mediated Non-Proteolytic Control of ETS2 Suppresses Nuclear Localization and Activity.
A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease …
Suppression of USP7 negatively regulates the stability of ETS proto-oncogene 2 protein.
CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-Raf/p-MEK/p-ERK …
ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST)
Enhancing Resilience in Young Stroke Survivors With Res-ET
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EB…
Mucomyst for Hepatitis C
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ